Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Celltrion Files Biosimilar without Japanese Clinical Data, More Firms Might Follow
October 24, 2025
- Earnings Season Kicks Off, Off-Year Revision Impact in Spotlight
October 24, 2025
- Santen Rolls Out Glaucoma Drug Setaneo in Japan
October 24, 2025
- FDA Again Rejects Mitsubishi Tanabe’s Parkinson’s Drug
October 24, 2025
- Kissei’s Linzagolix Approved for Uterine Fibroids in Taiwan
October 24, 2025
- And Pharma Group Subsidiaries Team Up for First Joint Promotion
October 23, 2025
- Takeda, Innovent Ink Oncology Deal for Bispecific, ADC Therapies
October 23, 2025
- Padcev/Keytruda Label Expansion Accepted for US FDA Review
October 23, 2025
- Astellas JV Aims to Bridge “Valley of Death” in Cell Therapy Manufacturing: CEO
October 22, 2025
- Krystal Launches Japan’s First DEB Therapy Vyjuvek Gel
October 22, 2025
- Japanese Drug Makers’ Domestic Sales Inch Up on Shift toward Specialty Areas: Fuji Keizai
October 22, 2025
- Sawai, Asahi Kasei Reach Settlement in Teribone Patent Suit
October 22, 2025
- Sumitomo Pharma Drops Option on FunPep’s FPP003 Peptide
October 22, 2025
- Daiichi Sankyo’s Anti-CDH6 ADC Hits Primary Goal in Global PII
October 22, 2025
- Daiichi Sankyo Unveils Dose-Escalation Data on TA-MUC1-Targeting ADC
October 22, 2025
- Taiho Secures Japan, Asian Rights to Arcus’ HIF-2α Inhibitor Casdatifan
October 21, 2025
- Santen Nabs Distribution Rights to Beovu, Lucentis in South Korea
October 21, 2025
- Chugai, Rani Therapeutics Strike Deal on Oral Antibody Drug
October 21, 2025
- Chugai to File Tecentriq for Adjuvant Bladder Cancer Use in 2026 after Positive Data
October 21, 2025
- Japan Approves Nonprescription Version of Morning-After Pill: ASKA
October 21, 2025
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…